Breaking News

FDA Accepts Rakuten Medical’s IND Application for Oncology Candidate

Will begin clinical studies of RM-1995 photoimmunotherapy in advanced head and neck cancer.

Author Image

By: Charlie Sternberg

Associate Editor

The U.S. Food and Drug Administration (FDA) has accepted Rakuten Medical Inc’s Investigational New Drug (IND) application to begin clinical studies of RM-1995 photoimmunotherapy in patients with advanced cutaneous squamous cell carcinoma or with head and neck squamous cell carcinoma.   RM-1995 photoimmunotherapy treatment is an investigational drug-device combination being developed by Rakuten Medical Inc. The drug portion of the treatment, RM-1995, is a conjugate of a photoactivatable dye (IR...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters